A Closer Look at Recent Data and Guideline Updates in CLL: Expert Perspectives on the Evolving Role of BTK Inhibitors and Combination Therapy

A continuing medical education activity provided by NAMCP and AAMCN

Recent Advances in the Treatment and Management of Chronic Lymphocytic Leukemia (CLL): Expert Perspectives on the Evolving Role of BTK Inhibitors and Combination Therapy
is a three-part webinar series

This is Part 1 of the series focusing on expert perspectives on the evolving role of BTK inhibitors

This activity is an archive from the webinar held March 10, 2021

This activity is valid from April 1, 2021 to April 1, 2023
 

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by an educational grant from
AstraZeneca

Description:
Chronic lymphocytic leukemia (CLL) is a cancer of the blood and bone marrow that affects older adults. CLL is the most common type of leukemia in adults. It affects B cell lymphocytes, which originate in the bone marrow, develop in the lymph nodes, and normally fight infection by producing antibodies. In 2021, it is expected that there will be 20,720 new cases of CLL and about 3,930 deaths. Fortunately for patients with CLL, several new treatments have recently become available, including BTK inhibitors, giving healthcare professionals many new options to improve patient outcomes with these new treatments and strategies.

Upon completion of this activity, participants will be able to:

  • Examine the clinical burden of chronic lymphocytic leukemia (CLL), including factors that contribute to poor prognosis and increased costs

  • Explore recent clinical data regarding mechanistic activity, efficacy, and safety of approved and emerging therapeutic options, and combination therapy, for chronic lymphocytic leukemia (CLL)

  • Evaluate the evolving role of next generation BTK inhibitors, and their combinations, in the first-line management of CLL

  • Compare and contrast BTK inhibitors, and their combinations, in the management of CLL, including their pharmacological differences

     

Faculty: John N. Allan, MD
Assistant Professor of Medicine
Weill Cornell Medicine

Disclosure:

Dr. Allan has served as a consultant for Abbvie, Janssen, PCYC, AstraZeneca, BeiGene, and Epizyme. Dr. Allan has served as an advisor for Abbvie, Janssen, PCYC, AstraZeneca, Ascentage Pharma, and Genetech. Dr. Allan has served as researcher for Janssen, AstraZeneca, and Genetech. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jeremy Williams has no real or perceived financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by an educational grant from
AstraZeneca

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue